本帖最后由 老马 于 2013-3-13 13:43 编辑 / ^7 n9 K$ n& P" ~1 F; ^
- m3 i' Q4 ] l) Q/ V- n; D
健择(吉西他滨)+顺铂+阿瓦斯汀
' N5 s8 w; g$ k& o% @ Gemzar +Cisplatin + Avastin7 X" h9 V9 K& K3 e* I; m6 Q
http://annonc.oxfordjournals.org/content/21/9/1804.full
3 A$ ?* R; b" x2 w tOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) % k5 Q9 e p+ B1 H* f
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. - @+ p) b0 K) X0 U& t: c4 I
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 2 W5 G; g; L8 ^8 f% Q" I) k
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1039)
- Z: J% G# L7 R8 O. F
华为网盘附件:
* U5 g. [, g K【华为网盘】ava.JPG- I* I0 O+ T k: q ~
|